Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Goserelin Acetate

FDA-approved product (implant, implantation), marketed as Zoladex.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Goserelin Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Gonadotropin releasing hormone analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli58.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Goserelin Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Goserelin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

    NCT07596212 · start 2026-09

    Registered record
    Registry ID
    NCT07596212
    Conditions
    Early-stage Breast Cancer; Hypoactive Sexual Desire Disorder; Hormone Receptor Positive Breast Carcinoma; Breast Cancer
    Interventions
    Aromatase Inhibitors; Bupropion; GnRH agonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2031-09
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly-stage Breast Cancer; Hypoactive Sexual Desire Disorder; Hormone Receptor Positive Breast Carcinoma; Breast Cancer
    InterventionAromatase Inhibitors; Bupropion; GnRH agonist
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer

    NCT07706933 · start 2026-08-01

    Registered record
    Registry ID
    NCT07706933
    Conditions
    Breast Cancer
    Interventions
    Dalpiciclib; Abemaciclib/Ribociclib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2033-06-30
    Enrolment
    456

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionDalpiciclib; Abemaciclib/Ribociclib
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients

    NCT07460752 · start 2026-05-22

    Registered record
    Registry ID
    NCT07460752
    Conditions
    Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Locally Advanced Hormone Receptor-Positive Breast Carcinoma
    Interventions
    Biospecimen Collection; Goserelin Acetate; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-05-22
    Completion
    2029-09-26
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Locally Advanced Hormone Receptor-Positive Breast Carcinoma
    InterventionBiospecimen Collection; Goserelin Acetate; Questionnaire Administration
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.

    NCT07450599 · start 2026-04-27

    Registered record
    Registry ID
    NCT07450599
    Conditions
    High-risk Localized Prostate Cancer
    Interventions
    Darolutamide; ADT
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-04-27
    Completion
    2030-10-15
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh-risk Localized Prostate Cancer
    InterventionDarolutamide; ADT
    PhasePhase 2
    Registry statusRecruiting

  • Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

    NCT07158021 · start 2026-01-22

    Registered record
    Registry ID
    NCT07158021
    Conditions
    Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma
    Interventions
    Biospecimen Collection; Electronic Health Record Review; Goserelin; Leuprolide; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-01-22
    Completion
    2028-01-01
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 +1 more
    InterventionBiospecimen Collection; Electronic Health Record Review; Goserelin; Leuprolide +1 more
    PhasePhase 2
    Registry statusRecruiting

  • The COSMYC Trial (COmbined Suppression of MYC)

    NCT06922318 · start 2025-08-19

    Registered record
    Registry ID
    NCT06922318
    Conditions
    Metastatic Castration-resistant Prostate Cancer
    Interventions
    ZEN-3694; Testosterone cypionate; Enzalutamide; Luteinizing hormone-releasing hormone (LHRH) analogue
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-19
    Completion
    2031-08-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer
    InterventionZEN-3694; Testosterone cypionate; Enzalutamide; Luteinizing hormone-releasing hormone (LHRH) analogue
    PhasePhase 2
    Registry statusRecruiting

  • Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

    NCT06832774 · start 2025-08-01

    Registered record
    Registry ID
    NCT06832774
    Conditions
    Prostate Cancer Metastatic Disease
    Interventions
    Local treatment; Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide).
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-01
    Completion
    2028-12-31
    Enrolment
    192

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic Disease
    InterventionLocal treatment; Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide).
    PhasePhase 2
    Registry statusRecruiting

  • Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

    NCT06291064 · start 2025-03-18

    Registered record
    Registry ID
    NCT06291064
    Conditions
    Triple Negative Breast Cancer
    Interventions
    Cyclophosphamide; Epirubicin; Docetaxel; Carboplatin; Breast Surgery; Capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-03-18
    Completion
    2032-06
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple Negative Breast Cancer
    InterventionCyclophosphamide; Epirubicin; Docetaxel; Carboplatin +2 more
    PhasePhase 2
    Registry statusRecruiting

  • Effect of a GnRH Analog on Hepatic Steatosis

    NCT06523530 · start 2024-11-26

    Registered record
    Registry ID
    NCT06523530
    Conditions
    Metabolic Dysfunction-Associated Steatotic Liver Disease; Nonalcoholic Fatty Liver; Endometriosis
    Interventions
    Goserelin Acetate 3.6 mg inj, implant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2024-11-26
    Completion
    2027-10
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic Dysfunction-Associated Steatotic Liver Disease; Nonalcoholic Fatty Liver; Endometriosis
    InterventionGoserelin Acetate 3.6 mg inj, implant
    PhasePhase 4
    Registry statusActive not recruiting

  • Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

    NCT06447623 · start 2024-02-01

    Registered record
    Registry ID
    NCT06447623
    Conditions
    Advanced Breast Cancer; HR+/HER2- Breast Cancer
    Interventions
    Apatinib; CDK4/6 Inhibitor; Aromatase inhibitor and Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-02-01
    Completion
    2029-02-01
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer; HR+/HER2- Breast Cancer
    InterventionApatinib; CDK4/6 Inhibitor; Aromatase inhibitor and Fulvestrant
    PhasePhase 3
    Registry statusRecruiting

  • Surgery and ART For Endometrioma

    NCT03717870 · start 2023-10

    Registered record
    Registry ID
    NCT03717870
    Conditions
    Ovarian Endometrioma; Infertility, Female
    Interventions
    Laparoscopic enucleation of ovarian endometrioma.; Prolonged pituitary downregulation; Assisted Reproductive Technology (ART)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2023-10
    Completion
    2027-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Endometrioma; Infertility, Female
    InterventionLaparoscopic enucleation of ovarian endometrioma.; Prolonged pituitary downregulation; Assisted Reproductive Technology (ART)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624

    NCT05781217 · start 2023-03-14

    Registered record
    Registry ID
    NCT05781217
    Conditions
    Prostate Cancer; Salvage Radiotherapy; Biochemical Recurrence; Androgen Deprivation Therapy; Metastases-free Survival
    Interventions
    triptorelin, goserelin, leuprorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-03-14
    Completion
    2032-12
    Enrolment
    534

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Salvage Radiotherapy; Biochemical Recurrence; Androgen Deprivation Therapy +1 more
    Interventiontriptorelin, goserelin, leuprorelin
    PhasePhase 3
    Registry statusRecruiting

  • Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

    NCT05498272 · start 2023-02-01

    Registered record
    Registry ID
    NCT05498272
    Conditions
    Prostate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma; High-Risk Cancer
    Interventions
    Olaparib; LHRH agonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-02-01
    Completion
    2026-12
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma +1 more
    InterventionOlaparib; LHRH agonist
    PhasePhase 2
    Registry statusActive not recruiting

  • Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole

    NCT05163106 · start 2022-12-01

    Registered record
    Registry ID
    NCT05163106
    Conditions
    Breast Cancer; HER2-negative Breast Cancer; ER-positive Breast Cancer; Locally Advanced Breast Cancer; Luminal A Breast Cancer; Luminal B Breast Cancer
    Interventions
    Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet; Goserelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-12-01
    Completion
    2024-07-30
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; HER2-negative Breast Cancer; ER-positive Breast Cancer; Locally Advanced Breast Cancer +2 more
    InterventionLetrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet; Goserelin
    PhasePhase 2
    Registry statusCompleted

  • Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy

    NCT07127315 · start 2022-06-01

    Registered record
    Registry ID
    NCT07127315
    Conditions
    Gonadotropin Releasing Hormone Agonists; Ovarian Function; Premenopausal; Breast Cancer; Chemotherapy
    Interventions
    Gonadotropin-releasing hormone agonist; Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-06-01
    Completion
    2024-07-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGonadotropin Releasing Hormone Agonists; Ovarian Function; Premenopausal; Breast Cancer +1 more
    InterventionGonadotropin-releasing hormone agonist; Chemotherapy
    PhaseNot applicable
    Registry statusCompleted